KRAS and glioblastoma: Bioluminescence imaging revealed that the group B (TBD0220-KRAS group) had a greater tumor burden and less survival time than the group A (TBD0220-WT group), indicating a strong tumorigenicity of the MES-GBM subtype (Figure 9B-D).